Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis

References

• Derwenskus J. Current disease-modifying treatment of multiple sclerosis. Mt Sinai J Med 2011;78:161-75
   PubMed Web of Science ®Google Scholar
• Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 1993;43:655-61
   Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-94
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Ford CC, et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler 2000;6:255-66
   PubMed Web of Science ®Google Scholar
• FDA. Fingolimod (Marketed as Gilenya) Prescribing and Labeling Information: Latest Label Approved on 20/07/2011. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022527s002lbl.pdf [Last accessed 26 March 2014]
   Google Scholar
• EMA. Gilenya Summary of Product Characteristics. 2012. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002202/WC500104528.pdf [Last accessed 26 March 2014]
   Google Scholar
• EMA. Tysabri Summary of Product Characteristics. 2011. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000603/WC500044686.pdf [Last accessed 26 March 2014]
   Google Scholar
• FDA. Natalizumab (Marketed as Tysabri) Prescribing and Labeling Information: Latest Label Approved 20/01/2012. 2012. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125104s0576lbl.pdf [Last accessed 26 March 2014]
   Google Scholar
• Calabresi PA, Goodin D, Jeffery D, et al. Efficacy and safety of fingolimod versus placebo: primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing–remitting multiple sclerosis. Abstract presented at the 28th Congress of the European Committee for Research and Treatment in Multiple Sclerosis, 10–13 October 2012, Lyon, France. Abstract available at: http://registration.akm.ch/einsicht.php?XNABSTRACT_ID=156899&XNSPRACHE_ID=2&XNKONGRESS_ID=171&XNMASKEN_ID=900 [Last accessed 24 March 2014]
   Google Scholar
• Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401
   PubMed Web of Science ®Google Scholar
• Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910
   PubMed Web of Science ®Google Scholar
• Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911-23
   PubMed Web of Science ®Google Scholar
• Karampampa K, Gustavsson A, Miltenburger C, Eckert B. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries. Mult Scler 2012;18:7-15
   PubMed Web of Science ®Google Scholar
• Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada. J Popul Ther Clin Pharmacol 2012;19:e11-25
   PubMedGoogle Scholar
• Kobelt G, Berg J, Atherly D, Hadjimichael O. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology 2006;66:1696-702
   PubMed Web of Science ®Google Scholar
• Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry 2006;77:918-26
   PubMed Web of Science ®Google Scholar
• Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in the United Kingdom. Eur J Health Econ 2006;7(Suppl 2):S96-104
   PubMedGoogle Scholar
• Bonafede MM, Johnson BH, Watson C. Health care-resource utilization before and after natalizumab initiation in multiple sclerosis patients in the US. Clinicoecon Outcomes Res 2013;6:11-20
   PubMedGoogle Scholar
• Raimundo K, Tian H, Zhou H, et al. Resource utilization, costs and treatment patterns of switching and discontinuing treatment of MS patients with high relapse activity. BMC Health Serv Res 2013;13:131
   PubMed Web of Science ®Google Scholar
• Chastek BJ, Oleen-Burkey M, Lopez-Bresnahan MV. Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims. J Med Econ 2010;13:618-25
   PubMedGoogle Scholar
• Ollendorf DA, Jilinskaia E, Oleen-Burkey M. Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. J Manag Care Pharm 2002;8:469-76
   PubMedGoogle Scholar
• Bergvall N, Makin C, Lahoz R, et al. Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study. PLOS One 2014;9:e88472
   PubMed Web of Science ®Google Scholar
• Bergvall N, Makin C, Lahoz R, et al. Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis. CMRO 2013;29:1647-56
   Google Scholar
• Bergvall N, Tambour M, Henriksson F, Fredrikson S. Cost-minimization analysis of fingolimod compared with natalizumab for the treatment of relapsing–remitting multiple sclerosis in Sweden. J Med Econ 2013;16:349-57
   PubMedGoogle Scholar
• Braune S, Lang M, Bergmann A. Second line use of fingolimod is as effective as natalizumab in a German out-patient RRMS-cohort. J Neurol 2013;260:2981-5
   PubMed Web of Science ®Google Scholar
• Graf C, Battisti WP, Bridges D, et al. Research methods & reporting. Good publication practice for communicating company sponsored medical research: the GPP2 guidelines. BMJ 2009;339:b4330
   PubMed Web of Science ®Google Scholar
• von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008;61:344-9
   PubMed Web of Science ®Google Scholar
• Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011;46:399-424
   PubMed Web of Science ®Google Scholar
• Halpern R, Agarwal S, Borton L, et al. Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: retrospective claims analysis. Adv Ther 2011;28:761-75
   PubMed Web of Science ®Google Scholar
• Lublin FD, Cofield SS, Cutter GR, et al. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol 2013;73:327-40
   PubMed Web of Science ®Google Scholar